Paper Raises Hundreds Of Questions About The Integrity Of Stem Cell Research Group
By Larry Husten,
Forbes
| 07. 02. 2013
Serious questions have been raised about the integrity and validity of research performed by a well-established German stem cell research group.
A paper published in the International Journal of Cardiology exhaustively details a multitude of discrepancies and contradictions in papers from the researcher’s group. Further, the revelation of such widespread misconduct may lead to broader disturbing questions about the reliability of scientific publications and the ability of the clinical research system to police itself.
In “Autologous bone marrow-derived stem cell therapy in heart disease: Discrepancies and contradictions,” Darrel Francis and colleagues scrutinize 48 papers from the research group of Bodo-Eckehard Strauer. According to Francis et al, the 48 papers from Strauer’s group contained reports on only 5 actual clinical studies, or “families” of reports, and that duplicate or overlapping reports were common. The paper contains details about more than 200 errors in the papers, including contradictory descriptions of the design, protocol and results of the trials. Francis et al write:
Readers cannot always tell whether a study is randomised versus not, open-controlled or blinded placebo-controlled, or lacking a control group...
Related Articles
By Emma Belmonte, ChinaFile | 10.03.2025
On the popular Chinese social media platform Xiaohongshu, also known as RedNote, an account called “Georgia Notes” (@格鲁吉亚小纸条) offers tips and advice to Chinese nationals planning a trip to the Republic of Georgia. In one post...
By Karin Hammarberg, Alex Polyakov, Catherine Mills, and Karinne Ludlow, The Conversation | 10.03.2025
Reports of several cases of embryo and sperm mix-ups have put the Australian fertility industry in the spotlight for all the wrong reasons.
These bungles have raised serious questions about the industry’s current model of self-regulation, and demonstrate a lack...
By Jared Whitlock, Endpoints News | 10.09.2025
When Nirnay Murthy learned about a treatment for his toddler son’s rare condition, relief quickly gave way to disappointment.
A one-time gene therapy called Zolgensma from the Swiss drugmaker Novartis can halt spinal muscular atrophy, a deadly condition that causes...
By Karin Hammarberg and Catherine Mills, BioNews | 10.13.2025
The Australian fertility industry has been rocked by several recent cases of embryo and sperm mix-ups. With a lack of transparency about what clinics do to prevent such errors recurring, trust and confidence in the industry and how it is...